Czasopismo
Tytuł artykułu
Warianty tytułu
Języki publikacji
Abstrakty
Cholesterol gallstone disease is often associated with the metabolic syndrome. Female gender is an unmodifiable risk factor for cholelithiasis and, in its turn, the metabolic syndrome features a sexual dimorphism which warns that a global approach might overlook important discrimination. We carried out a retrospective analytical case-control study in order to perform a comparative analysis between two groups of female patients with metabolic syndrome and gallstones (n=60) or without gallstones (n=65). All the patients were investigated by abdominal ultrasound and met at least three criteria for the diagnosis of metabolic syndrome. Cases and controls were compared regarding anthropometric measurements, a complex lipid profile, and liver function tests. The risks associated with the likelihood of gallstones were estimated by means of cross-tabulation. In order to rank the significant variables we developed a binary logistic regression model which identified lean body weight ≤ 46.44 kg (OR 0.165; 95% CI 0.045–0.611; P = 0.007), total cholesterol ≥ 4.9 mmol/L (OR 15.948; 95% CI 2.700–94.205; P = 0.002), and direct bilirubin > 5.1 µmol/L (OR 0.056; 95% CI 0.013–0.235; P < 0.001), as variables with significant probability of association with the risk of gallstones in women with metabolic syndrome.
Słowa kluczowe
Czasopismo
Rocznik
Tom
Numer
Strony
108-114
Opis fizyczny
Daty
wydano
2014-02-01
online
2014-02-04
Twórcy
autor
autor
autor
autor
Bibliografia
- [1] Shaffer E.A., Gallstone disease: Epidemiology of gallbladder stone disease, Best Pract. Res. Clin. Gastroenterol., 2006, 20(6), 981–996 http://dx.doi.org/10.1016/j.bpg.2006.05.004[Crossref]
- [2] Méndez-Sánchez N., Chavez-Tapia N.C., Motola-Kuba D., Sanchez-Lara K., Ponciano-Rodríguez G., Baptista H., Ramos M.H., Uribe M., Metabolic syndrome as a risk factor for gallstone disease, World J. Gastoenterol., 2005, 11(11), 1653–1657
- [3] Grundy S.M., Cholesterol gallstones: a fellow traveler with metabolic syndrome? Am. J. Clin. Nutr., 2004, 80(1), 1–2
- [4] Alberti K.G., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., Fruchart J.C., James W.P., Loria C.M., Smith S.C. Jr., Harmonizing the metabolic syndrome. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association, Circulation, 2009, 120, 1640–1645 [Crossref]
- [5] Kuk J., Ardern C.I., Age and sex differences in the clustering of metabolic syndrome factors, Diabetes Care, 2010, 33, 2457–2461 http://dx.doi.org/10.2337/dc10-0942[Crossref]
- [6] Stinton L.M., Myers R.P., Shaffer E.A., Epidemiology of gallstones, Gastroenterol. Clin. N. Am., 2010, 39(2), 157–169 http://dx.doi.org/10.1016/j.gtc.2010.02.003[Crossref]
- [7] Lobo R.A., Metabolic syndrome after menopause and the role of hormones, Maturitas, 2008, 60, 10–18 http://dx.doi.org/10.1016/j.maturitas.2008.02.008[WoS][Crossref]
- [8] Boland L.L., Folsom A.R., Rosamond W.D., Atherosclerosis Risk in Communities (ARIC) Study Investigators. Hyperinsulinemia dyslipidemia and obesity as risk factors for hospitalized gallbladder disease. A prospective study, Ann. Epidemiol., 2002, 12, 131–140 http://dx.doi.org/10.1016/S1047-2797(01)00260-5[Crossref]
- [9] Mosteller, R.D., Simplified calculation of body surface area, N. Engl. J. Med., 1987, 317(17), 1098 (letter)
- [10] Morgan D.J., Bray K.M., Lean body mass as a predictor of drug dosage. Implications for drug therapy, Clin. Pharmacokinet., 1994, 26(4), 292–307 http://dx.doi.org/10.2165/00003088-199426040-00005[Crossref]
- [11] Green B., Duffull S.B., What is the best size descriptor to use for pharmacokinetic studies in the obese? Br. J. Clin. Pharmacol., 2004, 58(2), 119–133 http://dx.doi.org/10.1111/j.1365-2125.2004.02157.x[Crossref]
- [12] Nam B.H., Kannel W.B., D’Agostino R.B., Search for an optimal atherogenic lipid risk profile: from the Framingham Study, Am. J. Cardiol., 2006, 97, 372–375 http://dx.doi.org/10.1016/j.amjcard.2005.08.055[Crossref]
- [13] Millán J., Pintó X., Muñoz A., Zúñiga M., Rubiés-Prat J., Pallardo L.F., Masana L., Mangas A., Hernandez-Mijares A., Gonzalez-Santos P., Ascaso J.F., Pedro-Botet J., Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention, Vasc. Health Risk Manag., 2009, 5, 757–765
- [14] Kahn H.S., The Lipid Accumulation Product Is Better Than BMI for Identifying Diabetes. A population-based comparison, Diabetes Care, 2006, 29(1), 151–153 http://dx.doi.org/10.2337/diacare.29.01.06.dc05-1805[Crossref]
- [15] McLaughlin T., Reaven G., Abbasi F., Lamendola C., Saad M., Waters D., Simon J., Krauss R.M., Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am. J. Cardiol., 2005, 96(3), 399–404 http://dx.doi.org/10.1016/j.amjcard.2005.03.085[Crossref]
- [16] Ruhl C.E., Everhart J.E., Association of diabetes, serum insulin, and C-peptide with gallbladder disease, Hepatology, 2000, 31(2), 299–303 http://dx.doi.org/10.1002/hep.510310206[Crossref]
- [17] Tsai C.J., Leitzmann M.F., Willett W.C., Giovannucci E.L., Prospective study of abdominal adiposity and gallstone disease in US men, Am. J. Clin. Nutr., 2004, 80(1), 38–44
- [18] Chen L.Y., Qiao Q.H., Zhang S.C., Chen Y.H., Chao G.Q., Fang L.Z., Metabolic syndrome and gallstone disease, World J. Gastroenterol., 2012, 18(31), 4215–4220 http://dx.doi.org/10.3748/wjg.v18.i31.4215[Crossref]
- [19] Sporea I., Goldis M., Mateoc A., Echographic screening concerning the incidence of gallstones in a general population, Gastroenterol., 1993, 104, A379
- [20] Acalovschi M., Pascu M., Iobagiu S., Petrescu M., Olinici C.D., Increasing gallstones prevalence and cholecystectomy rate in a large Romanian town, Dig. Dis. Sci., 1995, 40, 2582–2586 http://dx.doi.org/10.1007/BF02220445[Crossref]
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.-psjd-doi-10_2478_s11536-013-0255-5